Know Cancer

forgot password

A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma

Phase 2
18 Years
Not Enrolling
Anaplastic Large-Cell Lymphoma

Thank you

Trial Information

A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma

SGN-30 is the chimeric form of a novel murine monoclonal antibody (mAb), AC-10, that has
specificity for CD30. The CD30 antigen has a very low expression on normal cells, but is
expressed on malignant cells in Hodgkins disease and anaplastic large cell lymphoma.

This study is designed to define the toxicity profile and antitumor activity of SGN-30 in
patients with refractory or recurrent Hodgkin's disease and with refractory or recurrent
anaplastic large cell lymphoma. Patients will receive 6 weekly intravenous (IV) infusions
of SGN-30 followed by a 4 week observation period.

Inclusion Criteria:

- Patients must have refractory or recurrent HD or refractory or recurrent ALCL.

- Patients must have histologically confirmed CD30+ HD or ALCL.

- Patients must have bidimensional measurable disease on physical examination or
radiologic evaluation.

- Patients must have failed systemic chemotherapy either as initial therapy for
advanced disease or as salvage therapy after initial radiotherapy for early stage

- Patients may have received no more than four treatments (radiation, chemotherapy,
and/or biologics) prior to enrollment.

- Patients may have received no more than one stem cell transplantation.

- Patients who have undergone stem cell transplantation must have received at least one
therapy post-transplantation. Patients who have not had stem cell transplantation
must be considered ineligible or refuse treatment by stem cell transplantation.

- Patients must have completed radiotherapy and/or chemotherapy at least four weeks
prior to enrollment. Any prior treatment with nitrogen mustard agents, melphalan, or
BCNU must have been completed at least six weeks prior to enrollment.

- Patients must have an ECOG performance status of ≤ 2 and a life expectancy > three

- Patients must be at least 18 years of age.

- Patients must be available for periodic blood sampling, study-related assessments,
and management of toxicity at the treating institution.

- Females of childbearing potential must have a negative β-HCG pregnancy test result
within three days of enrollment. All patients must agree to use an effective
contraceptive method during the course of the study.

- Patients must give written informed consent. A copy of the signed informed consent
form will be retained in the patient's chart.

- Patients must meet baseline lab data requirements.

Exclusion Criteria:

- Patients with primary cutaneous ALCL

- Patients who have been treated previously with any anti-CD30 antibody

- Patients who have received any mAb unless a recent serum testing reveals no antibody
titer and no evidence of human anti-murine antibodies (HAMA) or human anti-chimeric
antibodies (HACA) in the peripheral circulation

- Patients receiving any investigational biological agent within eight weeks of
enrollment or any other investigational agent within four weeks of enrollment

- Patients with a known hypersensitivity to recombinant proteins or any excipient
contained in the drug formulation

- Patients with a history of other malignancies during the past five years with the
exception of adequately treated basal or squamous cell skin cancer or cervical
carcinoma in situ

- Patients with known active viral, bacterial, or systemic fungal infection; patients
who are known to be HIV, Hepatitis B, or Hepatitis C positive.

- Patients with symptomatic cardiac disease including ventricular dysfunction, coronary
artery disease, or arrhythmias

- Patients with symptomatic brain metastases requiring treatment

- Patients who are pregnant or breastfeeding

- Patients with any serious underlying medical condition that would impair their
ability to receive or tolerate the planned treatment

- Patients with dementia or altered mental status that would preclude understanding and
rendering of informed consent

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


United States: Food and Drug Administration

Study ID:




Start Date:

February 2004

Completion Date:

December 2006

Related Keywords:

  • Anaplastic Large-Cell Lymphoma
  • Anaplastic Large-Cell Lymphoma
  • Lymphoma
  • antigens, CD30
  • Monoclonal Antibody
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Anaplastic



Roswell Park Cancer Institute Buffalo, New York  14263
Washington University School of Medicine Saint Louis, Missouri  63110
University of Minnesota Minneapolis, Minnesota  55455
University of Washington Seattle, Washington  98195
Duke University Medical Center Durham, North Carolina  27710
Georgetown University Washington, District of Columbia  20007-2197
Northwestern University Chicago, Illinois  60611
University of Rochester Rochester, New York  14642
Dana Farber Cancer Institute Boston, Massachusetts  02115
University of Texas MD Anderson Cancer Center Houston, Texas  77030
University of Miami Miami, Florida  33136
University of Alabama, Birmingham Birmingham, Alabama  35233
Kaiser Permanente Portland, Oregon  97227
University of Nebraska Omaha, Nebraska  68198
Oregon Health Science University Portland, Oregon  97239
Cornell University New York, New York  10021
University of Califorinia at Los Angeles Los Angeles, California  91342
University of Maryland Greenebaum Cancer Center Baltimore, Maryland  21201